高血压是临床常见的慢性心血管疾病之一，也是心脑血管并发症的主要危险因素。研究发现，血管壁结构与功能异常及血压水平持续升高所导致的血管重塑，可损害心脏、肾脏、脑等器官，进而增加罹患动脉粥样硬化、心力衰竭等严重并发症的风险。线粒体自噬是线粒体质量控制体系的关键一环，在高血压及其并发症的发生发展中具有重要作用，提示线粒体自噬相关基因、蛋白等可能成为疾病的治疗靶点。中药疗法具有多组分、多靶点、增效减毒等优势，在防治疾病方面疗效显著。中药活性成分可通过调控张力蛋白同源基因诱导激酶1/E3泛素连接酶等相关信号通路，改善自噬相关蛋白或基因表达，调控血管平滑肌细胞及内皮细胞、心肌细胞、神经元线粒体自噬水平，进而抑制高血压及心脑血管系统并发症的发生发展。通过对近年来中药活性成分调控线粒体自噬治疗高血压及其并发症中的研究进行总结，为该病临床诊治提供新的思路与方法。

Hypertension is one of the prevalent chronic cardiovascular diseases in clinical practice and a major risk factor for cardiocerebrovascular complications. Recent studies have revealed that vascular remodeling, driven by structural and functional disturbances in the vascular wall and sustained elevations in blood pressure, can impair vital organs such as the heart, kidneys, and brain, thereby increasing the risk of severe complications such as atherosclerosis and heart failure. Mitophagy, a crucial component of mitochondrial quality control systems, plays a pivotal role in the pathogenesis and progression of hypertension and its complications, suggesting that mitophagy-related genes and proteins may serve as molecular therapeutic targets for hypertension and its complications. Traditional Chinese medicine (TCM) therapy, characterized by its multi-component, multi-target, and synergistic yet toxicity-reducing properties, exhibits remarkable efficacy in disease prevention and treatment. Active constituents of TCM can regulate the PTEN-induced putative kinase 1/E3 ubiquitin ligase and other related signaling pathways, thereby improving the expression of autophagy-related proteins or genes and regulating mitophagy in vascular smooth muscle cells, endothelial cells, cardiomyocytes, and neurons, this regulation inhibits the development of hypertension and its cardiocerebrovascular complications. This review summarizes and consolidates recent research findings on the regulation of mitophagy by active ingredients in TCM for treatment of hypertension and its complications, aiming to provide novel insights and methodologies for the clinical diagnosis and treatment of this disease.

R285

国家中医药管理局第五批全国中医临床优秀人才研修项目（国中医药人教函 [2022] 1号）；济宁医学院大学生创新训练计划项目（cx2023029z）；济宁医学院2022年度本科教学改革研究项目（zd202213）；济宁医学院实验教学和教学实验室建设研究项目（SY2024024）